On June 26, the ministry of commerce released the 2017 analysis report on the circulation market of Chinese medicinal materials. This is the fifth consecutive year that the ministry of commerce has released the analysis report on the circulation market of Chinese medicinal materials, analyzed the domestic market situation of Chinese medicinal materials and the import and export trade situation of Chinese medicinal materials in 2017, and forecasted the circulation development trend of Chinese medicinal materials.

Professionals to the author said that the above price increase or fall in the variety, most of the drugs are too narrow range of small varieties. The market price of these varieties is often very obvious. Moreover, its market demand is not big, once the production comes up, it is easy to drop the price, and it is not easy for the price to rebound.

Prices in the table above 2017 civil sweet, in fact, the original is only more than ten dollars, so far this year has dropped a few bucks, prices fell sharply. The price of umme, which also rose sharply in 2017, has fallen by several yuan.

This professional person thinks, a few cold back strange medicinal materials breed, cannot represent industry whole trend. The overall situation of the Chinese medicine industry still needs to be seen from the comprehensive situation of large varieties.

As for the research and judgment on the development trend of Chinese medicinal materials circulation, the report also mentioned that the trend of Chinese medicinal materials in 2018 is expected to be similar to that in 2015, and the overall shock adjustment will be made. Among them, the price of large domestic varieties is hard to be optimistic, while the price of small varieties, wild varieties and animal varieties is expected to go up.

▍ drug companies to accelerate the production layout

The importance of traditional Chinese medicine for Chinese medicine decoction and traditional Chinese medicine is self-evident. It is not only the source of quality control, but also the key factor affecting the price.

In the past two years, the quality and resource control of Chinese medicinal materials has been the focus of attention and heated discussions in the industry. Therefore, raw materials have become the focus of the industrial chain of many pharmaceutical companies.

, according to a report by the Chinese traditional medicine protection and development planning, "" to the Chinese traditional medicine extends the industrial chain of origin" requirements, Chinese herbal medicine, sig, tasly, heaven and earth, treasured island, kyushu, fragrant snow of the listed company, with a variety of forms in succession sinking origin, origin resource competition.

It is understood that, at present, many traditional Chinese medicine enterprises, such as kangmei, xiang xue, all have their own base of Chinese medicine.

According to public information, sig has in guangdong, Beijing, sichuan, anhui, Shanghai and other places to make acquisitions layout, the future is expected to continue to increase the national layout, self-built production base in the local or buy local scale production enterprises, further enhance the market share.